Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines
☆
Ann Oncol
.
2021 Feb;32(2):157-170.
doi: 10.1016/j.annonc.2020.11.005.
Epub 2020 Nov 25.
Authors
M E Lacouture
1
,
V Sibaud
2
,
P A Gerber
3
,
C van den Hurk
4
,
P Fernández-Peñas
5
,
D Santini
6
,
F Jahn
7
,
K Jordan
8
,
ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
Affiliations
1
Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
2
Department of Oncodermatology, Claudius Regaud Institute, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France.
3
Department of Dermatology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany.
4
Department of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, the Netherlands.
5
Department of Dermatology, The University of Sydney, Westmead Hospital, Sydney, Australia.
6
Arcispedale Santa Maria Nuova di Reggio Emilia, Reggio Emilia, Italy; Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy.
7
Department of Internal Medicine IV, Hematology, Oncology, Martin-Luther-University Halle-Wittenberg, Halle, Germany.
8
Department of Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
PMID:
33248228
DOI:
10.1016/j.annonc.2020.11.005
No abstract available
Publication types
Practice Guideline